Heterogeneity in detecting Abl kinase mutations and better sensitivity using circulating plasma RNA
Authors:
Open Access
- 24 August 2006
- journal article
- research article
- Published by Springer Nature in Leukemia
- Vol. 20 (11) , 1989-1991
Abstract
Most studies test for mutations in the kinase domain of the abl gene in chronic myeloid leukemia (CML) using peripheral blood (PB) cells. Frequently, progression of the disease manifests with increased blasts in bone marrow (BM) and not in PB. Simultaneous analysis of plasma, PB cells and BM cells from 41 imatinib-resistent CML patients showed mutations in 63% of PB cells and 68% of plasma or BM cells (P=0.04). In discordant patients, 13 mutations were detected in plasma, 11 in BM cells and 9 in PB cells. The T315I mutation was detected in plasma and BM but not PB cells in one patient. We detected no mutations in the plasma of 45 previously untreated CML patients, but two of these patients showed mutations in plasma and not cells by 9 months on therapy. Circulating plasma mRNA is a reliable alternative to BM mRNA for detecting ABL mutations.Keywords
This publication has 13 references indexed in Scilit:
- The development of imatinib as a therapeutic agent for chronic myeloid leukemiaBlood, 2005
- Characterization of AMN107, a selective inhibitor of native and mutant Bcr-AblCancer Cell, 2005
- Free circulating soluble CD52 as a tumor marker in chronic lymphocytic leukemia and its implication in therapy with anti‐CD52 antibodiesCancer, 2004
- Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistanceLeukemia, 2004
- Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon α/ara-CLeukemia, 2003
- Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosisBlood, 2003
- Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significanceBlood, 2003
- Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid LeukemiaNew England Journal of Medicine, 2003
- Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous LeukemiaNew England Journal of Medicine, 2002
- Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or AmplificationScience, 2001